HealthQuartzabout 2 hours ago
AstraZeneca partners with AI firm Insitro
2 min read
AstraZeneca announced a drug discovery collaboration with AI biotech Insitro valued at up to $1.5 billion. The deal targets metabolic dysfunction-associated steatohepatitis and cardiomyopathies, with Insitro receiving $40 million upfront and potential future payments. AstraZeneca retains sole global rights to emerging programs while Insitro uses its Virtual Human AI platform for early discovery.
Level
Hype check
Tap to vote and see what everyone thinks.
